Pentoxifylline Injection 5ml: 0.1g GMP Plant

• Customization: Available
• Application: Internal Medicine
• Usage Mode: Injection
• Model NO.: 5ml: 0.1g
• Suitable for: Elderly, Adult
• State: Liquid
• Shape: Solution
• Type: Inorganic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Production Line: GMP Approved
• Transport Package: Carton
• Specification: 5ml: 0.1g
• Trademark: SHIMEN
• Origin: He
• HS Code: 3009909099
• Production Capacity: 1000000

Product Description

Pentoxifylline  Injection
 

Product name: Pentoxifylline Injection
Dosage: Intravenous drip. The patient should be in a lying position when administered. The initial dose is 100mg of hexoketococine, which should be administered within 2-3 hours, and the maximum drip rate should not exceed 100mg/hour, which can be increased by 50mg each time according to the patient's tolerance, and the usual dose is 100-200mg each time, 1-2 times a day, and the maximum dose should not exceed 300mg each time.

Indication:  Regular drug for cardiovascular department, safer in the plastic bottle packaging

   It applies to the brain blood circulation disorders such as transient ischemic attack, stroke sequelae and cerebral dysfunction caused by cerebral ischemia;

   Peripheral blood circulation disorders such as thromboembolic vasculitis, abdominal artery occlusion, intermittent claudication or rest pain.

Shijiazhuang No. 4 Pharmaceutical Co., Ltd., as one of the leading manufacturers in Chinese pharmaceutical industry and a well-known brand, has a business history of seventy years. The company principally specializes in R & D, manufacture and sales of wide types of drugs mainly including intravenous infusion.
The production lines have achieved full automation control and information control in the production process and logistics process and reached international advanced level by integrating the world's leading equipment and technology.
With product quality as its life, the Company always organizes production in strict accordance with GMP requirements, establishes and implements superior service concepts and measures and provides guarantee for the health of the majority of patients at home and abroad with excellent quality products and services.
The Company has a powerful R&D team and made a number of achievements in scientific research and undertaken many major scientific and technological innovation projects and industrialization projects by firmly grasping the pulse of pharmaceutical development, increasing new product development investment and accelerating the pace of technological innovation.
Large volume injection is the key products, tablets, capsules, small volume injection and other forms are manufactured also. Recently API has been put into production and sales. There are more than ten international advanced production lines for the large volume injection, its production scale, technology level, brand influence and economic benefit are on the forefront of domestic counterparts, and it has become one of China's top 100 pharmaceutical industry enterprises and China's top 10 chemical and pharmaceutical industry preparation export-oriented excellent enterprise brands for many consecutive years.
The products are radiated to all provinces, autonomous regions and municipalities in China and also exported to many overseas markets, including more than 80 countries in Asia, Americas, Europe, Oceania, Africa and other continents, and it has become one of the main export enterprises of infusion products.